Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 20/20 | 0.81 |
| ▸ | AVPR1A | P37288 | 11/20 | 0.81 |
| ▸ | OXTR | P30559 | 11/20 | 0.81 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.81 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5338944 | 1.00 | AVPR1B (0.81) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5348130 | 0.93 | AVPR1B (0.83) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5348745 | 0.93 | AVPR1B (0.83) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5348138 | 0.93 | AVPR1B (0.83) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5351532 | 0.93 | AVPR1B (0.78) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5341118 | 0.93 | AVPR1B (0.82) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5346504 | 0.93 | AVPR1B (0.82) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL7399213 | 0.93 | AVPR1B (0.87) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5352013 | 0.93 | AVPR1B (0.87) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5352769 | 0.91 | AVPR1B (0.80) | AVPR1BAVPR1AOXTRAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202267-B2 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | SANOFI-AVENTIS (FR) | 2007-04-10 | — | — | US | claimed |
| US-20050192335-A1 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | US | claimed |
| US-7202267-B2 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | SANOFI-AVENTIS (FR) | 2007-04-10 | — | — | US | disclosed |
| US-20050192335-A1 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192335-A1 | Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic | HCAR3, MC2R, NPR3 | AVPR1B 101/4885AVPR1A 128/4885OXTR 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.